Skip to main content
OpenTrials
Completed

NCT Number: NCT03353961

Internet Delivered ERITA for Nonsuicidal Self-Injury

To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council, Stockholm, Sweden

Loading trial locations.

About this study

Statistical Analyses

Treatment effects will be evaluated according to the intention-to-treat principle. Primary end-point for all outcomes is post-treatment. Secondary end-point include a controlled 3 month follow-up.

Primary Analysis

The primary outcome analysis will include treatment group (ERITA , TAU) and weekly reports of NSSI frequency measured once every week 4 weeks prior to treatment start, once every week during treatment, and once every week four weeks after treatment termination. Regression analysis modelled for count data will be used to estimate trend over time. Four weeks after treatment termination will be considered primary endpoint. Pairwise contrasts (group x time interaction) from the regression model will be used to evaluate between-group differences at primary endpoint (4 weeks after treatment termination).

Secondary Analyses

Secondary outcomes measured once before, during, and after treatment will be analyzed in a similar fashion as for the primary outcome, modelled after data's distribution (count or continuous). Measures collected only once at baseline and post-treatment will be analyzed with regression analyses including treatment group (online ERITA , TAU) as the between-subjects factor, time (baseline to post) as the within-subjects factor, and group × time interactions, modelled after data's distribution (count or continuous).

Parallel process latent growth curve modeling will be used to determine whether change in week-to-week emotion dysregulation (DERS-16) during treatment mediate the overall effect of ERITA+ETAU on week-to-week change in the primary outcome self-rated NSSI frequency (DSHI-Y).

3 Month Follow-Up

Data collected at 3-month follow-up will be used to determine the extent to which potential treatment gains were maintained both within and between treatment conditions

Update 28 April 2022: As a secondary analyses, we also aim to investigate the effect of treatment moderators (primary aim) and predictors (secondary aim) on NSSI frequency one month after treatment termination. This update was submitted prior to conducting the analyses.

The selection of potential moderators was theoretically and empirically motivated. We will investigate the following variables (measured at baseline):

Age Difficulties in emotion regulation As measured with the Difficulties in Emotion Regulation Scale - 36 item version (DERS) Past month NSSI frequency As measured with the Deliberate Self-Harm Inventory Youth version (DSHI-Y) Global functioning As measured with the Childrens Global Assessment Scale Depressive symptoms As measured with the 21-item Depression Anxiety Stress Scales (DASS-21) Sleep difficulties As measured with the Insomnia Severity Index (ISI) Parental Minimization - discounting or devaluing the child's negative emotions/problems As measured with The Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A), subscale minimazation Level of suicidality As measured with the MINI-KID International Neuropsychiatric Interview, version 6

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 5 nonsuicidal self-injury episodes past year
  • ≥ 1 nonsuicidal self-injury episodes past month
  • having at least one parent who committed to participate in the parent program

Exclusion criteria

  • Severe suicidal ideation
  • a diagnosis of psychotic or bipolar I disorder or ongoing (past month) substance dependence
  • the presence of co-occurring psychological disorders that required immediate treatment (i.e., severe anorexia nervosa)
  • insufficient understanding of the Swedish language

Treatment and study plan

Emotion regulation individual therapy

Behavioral

The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.

Treatment as Usual

Behavioral

Treatment as usual as provided in the community.

Primary outcomes

  1. Deliberate Self-Harm Inventory Youth version (DSHI-Y)

    Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended

    Frequency of nonsuicidal self-injury

Secondary outcomes

  1. Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)

    Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended

    Difficulties in emotion regulation as primary potential mechanism of change. Ranges from 16-80, with higher scores indicating more difficulties.

  2. Difficulties in Emotion Regulation Scale - 36 item version (DERS)

    Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Difficulties in emotion regulation. Ranges from 36-180, with higher scores indicating more difficulties.

  3. the 21-item Depression Anxiety Stress Scales (DASS-21)

    Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Symptoms of depression, anxiety and stress. Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating more symptoms.

  4. Borderline Symptom List Supplement

    Time frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended

    Impulsive self-destructive behaviors

  5. Acceptance and Action Questionnaire

    Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Acceptance and valued actions. Ranges from 7-49, with higher scores indicating less acceptance and valued actions.

  6. Childrens Global Assessment Scale

    Time frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended

    Global functioning. Ranges from 1-100, with higher scores indicating better functioning.

  7. The Clinical Global Impressions -Severity and Improvement scales

    Time frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended

    Global symptom severity and improvement. Severity of illness scale ranges from 1-7, with higher scores indicating higher severity of illness. Global improvement scale ranges from 1-7 with lower scores indicating more improvement.

Other outcomes

  1. Short version of the Experiences in Close Relationships Scale - Revised Child version

    Time frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)

    Experiences in close relationships. Ranges from 12-84, with higher scores indicating greater problems.

  2. Generalised Anxiety Disorder 7-item scale

    Time frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)

    Worry. Ranges 0-21, with higher scores indicating more worry.

  3. Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version

    Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Costs associated with psychiatric illness

  4. Kidscreen-10

    Time frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Quality of life. Ranges 11-55, with higher scores indicating higher quality in life.

  5. Patient Internet-delivered cognitive behavioral Adherence Scale

    Time frame: 6 and 12 weeks after baseline

    Patient adherence to treatment. Ranges from 0-20, with higher scores indicating higher adherence.

  6. Working Alliance Inventory

    Time frame: 4 weeks after treatment starts

    Working alliance with online therapist

  7. The Coping with Children's Negative Emotions Scale Adolescent Version

    Time frame: Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended

    Parents' perceived ability to cope with children's negative emotions. Three subscales will be used derived to reflect the specific types of coping response parents tend to use in these situations (punitive reactions, problem focused reactions, and minimization reactions). Each subscale ranges from 1-7.

  8. The Client Satisfaction Questionnaire

    Time frame: 12 weeks after treatment starts

    Client satisfaction with treatment. Ranges from 8-32 with higher scores indicating greater treatment satisfaction.

  9. Adverse Events

    Time frame: 12 weeks after treatment starts

    Self-rating scale that measures adverse events related to treatment

  10. Credibility/Expectancy Questionnaire

    Time frame: 1 week after treatment starts

    Treatment credibility and expectancy. Ranges from 0-50 with higher scores indicating greater credibility/expectancy.

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Official study title

Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study

Acronym: ERITA

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Nov 27, 2017
Registry last updated
May 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.